Growth of primary tumors receiving in situ Flt3L and TLR3/CD40 agonists was not altered by irradiating distant tumors (Fig. 2f), emphasizing the requirement for targeting the same tumor to achieve maximal tumor control by ISIM. The gene discussed is TLR3; the disease is neoplasm.